- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
New Zealand Study Reveals Importance of Patient Attitudes Toward Biosimilars
Patients who research medical information online are likely to be more concerned about switching from originator products to biosimilars, according to the study.
A New Zealand study of patients with rheumatic conditions suggests that providers need to be mindful of patient attitudes toward biosimilars to prevent biased therapy choices and poor outcomes.
Patients who do online searching for medical information about biosimilars are liable to have exacerbated concerns about switching to biosimilars, according to the study, which examined patient attitudes toward these agents. The findings also indicated that women are more likely to have concerns about switching from originator drugs to biosimilars.
Among the findings:
- There was a positive correlation between adverse events experiences from the originator and adverse events anticipated from the biosimilar (P < .001.
- There was a positive association between perceptions of originator safety and the expectation that biosimilars are unsafe (P <.001).
- There was a significant negative association between the perceived effectiveness of the current originator and a preference for a biosimilar medicine (P <.001).
To read more about the findings, visit The Center for Biosimilars.
How Health Care Institutions Can Leverage Biosimilars to Generate Savings
August 17th 2022On this episode of Managed Care Cast, Ryan Haumschild, PharmD, MS, MBA, from Emory Healthcare and the Winship Cancer Institute, explains the evolution of biosimilar pharmacoeconomics and the different strategies that health care institutions can implement to reap the benefits of biosimilar savings.
Listen
FDA Q&A: Addressing Biosimilar Safety, AI in Drug Development, and Supply Chain Challenges
November 6th 2024In a Q&A, an FDA spokesperson discusses efforts to reduce misinformation about biosimilars through education, the agency’s collaboration with global regulators to streamline development, and its work to address drug shortages while emphasizing safety, efficacy, and public trust.
Read More
Exploring the Complexities of Biosimilars and Interchangeability
October 30th 2024A panel of industry experts discussed the complexities of biosimilars and interchangeability, emphasizing the challenges in adoption, the need for regulatory and legislative solutions, and the importance of education to combat misinformation.
Read More
